211 related articles for article (PubMed ID: 28345112)
1. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 Mar; 36(2):137-140. PubMed ID: 28345112
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
Castells L; Llaneras J; Campos-Varela I; Bilbao I; Crespo M; Len O; Rodríguez-Frías F; Charco R; Salcedo T; Esteban JI; Esteban-Mur R
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):86-93. PubMed ID: 28051797
[TBL] [Abstract][Full Text] [Related]
4. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
[TBL] [Abstract][Full Text] [Related]
5. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
[TBL] [Abstract][Full Text] [Related]
6. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
9. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
[TBL] [Abstract][Full Text] [Related]
11. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
12. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
He YL; Yang SJ; Hu CH; Dong J; Gao H; Yan TT; Liu JF; Yang Y; Ren DF; Zhu L; Zhao YR; Chen TY
Aliment Pharmacol Ther; 2018 Feb; 47(4):526-532. PubMed ID: 29250808
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
15. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Mucenic M; Bandeira de Mello Brandao A; Marroni CA; Medeiros Fleck A; Zanotelli ML; Kiss G; Meine MH; Leipnitz I; Soares Schlindwein E; Martini J; Costabeber AM; Sacco FKF; Cracco Cantisani GP
Transplant Proc; 2018 Apr; 50(3):769-771. PubMed ID: 29661434
[TBL] [Abstract][Full Text] [Related]
19. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial.
Cheema SUR; Rehman MS; Hussain G; Cheema SS; Gilani N
BMC Nephrol; 2019 Nov; 20(1):438. PubMed ID: 31779583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
